Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
出版年份 2019 全文链接
标题
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
作者
关键词
-
出版物
HEART FAILURE REVIEWS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-12-13
DOI
10.1007/s10741-019-09874-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
- (2018) Ricky D. Turgeon et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan
- (2018) Satoshi Kodera et al. CIRCULATION JOURNAL
- Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease
- (2018) Manon C. Stam-Slob et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
- (2018) Radya Kumar et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
- (2018) Parth Shah Current Cardiology Reports
- Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Hmwe Hmwe Kyu et al. LANCET
- Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
- (2017) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Mohsen Naghavi et al. LANCET
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review of the cost-effectiveness of influenza immunization programs
- (2017) Eon E.K. Ting et al. VACCINE
- Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
- (2017) Peter P. Toth et al. Journal of the American Heart Association
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
- (2017) Gregg C. Fonarow et al. JAMA Cardiology
- Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
- (2017) Alejandro Arrieta et al. PLoS One
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
- (2016) Shravanthi R. Gandra et al. CLINICAL CARDIOLOGY
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial Hypercholesterolemia
- (2016) Jennifer G. Robinson PROGRESS IN CARDIOVASCULAR DISEASES
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started